Daniel Heng, Head of Medical Oncology at the Arthur J.E. Child Comprehensive Cancer Centre in Calgary, Alberta, shared on X:
“EV Prembrolizumab for metastatic bladder cancer: CR rates are high and their duration of response long. Definitely the standard of care. CR patients had an average of 13 cycles of EV. Optimizing and learning about EV dosing and weaning in CR patients is important.”
